

# Brigid S Boland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4962477/publications.pdf>

Version: 2024-02-01

58  
papers

3,217  
citations

218381

26  
h-index

168136

53  
g-index

61  
all docs

61  
docs citations

61  
times ranked

5343  
citing authors

#	ARTICLE	IF	CITATIONS
1	A gp130 Src-YAP module links inflammation to epithelial regeneration. <i>Nature</i> , 2015, 519, 57-62.	13.7	528
2	Global chemical effects of the microbiome include new bile-acid conjugations. <i>Nature</i> , 2020, 579, 123-129.	13.7	316
3	The Real-World Effectiveness and Safety of Vedolizumab for Moderate to Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2016, 111, 1147-1155.	0.2	257
4	Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 635-643.	0.6	147
5	Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. <i>Science Immunology</i> , 2020, 5, .	5.6	127
6	Early precursors and molecular determinants of tissue-resident memory CD8 <sup>+</sup> T lymphocytes revealed by single-cell RNA sequencing. <i>Science Immunology</i> , 2020, 5, .	5.6	124
7	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1345.	0.2	119
8	Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 159, 1262-1275.e7.	0.6	101
9	The TRPA1 ion channel is expressed in CD4 <sup>+</sup> T cells and restrains T-cell-mediated colitis through inhibition of TRPV1. <i>Gut</i> , 2017, 66, 1584-1596.	6.1	98
10	Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e132.	1.3	97
11	Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases?. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2634-2643.	2.4	85
12	Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1031-1038.	1.9	80
13	Delineation of a molecularly distinct terminally differentiated memory CD8 T cell population. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25667-25678.	3.3	73
14	Update on Janus Kinase Antagonists in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 603-617.	1.0	70
15	Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9192-E9200.	3.3	66
16	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10.	0.6	65
17	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1533-1540.e2.	2.4	60
18	Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 270-282.	0.9	48

#	ARTICLE	IF	CITATIONS
19	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	2.4	48
20	Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads. <i>Genome Biology</i> , 2019, 20, 226.	3.8	47
21	Integrin Activation Controls Regulatory T Cell-Mediated Peripheral Tolerance. <i>Journal of Immunology</i> , 2018, 200, 4012-4023.	0.4	44
22	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 733-745.	0.2	42
23	Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 848-857.	1.9	40
24	Host engulfment pathway controls inflammation in inflammatory bowel disease. <i>FEBS Journal</i> , 2020, 287, 3967-3988.	2.2	40
25	Association of Serum Bilirubin with Aging and Mortality. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 1-7.	0.4	38
26	Immunodeficiency and Autoimmune Enterocolopathy Linked to NFAT5 Haploinsufficiency. <i>Journal of Immunology</i> , 2015, 194, 2551-2560.	0.4	32
27	Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 410-420.	0.9	28
28	Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 511-518.e6.	2.4	28
29	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1008-1016.	1.9	27
30	Serum Concentrations of $\gamma$ -hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2722-2730.e4.	2.4	26
31	Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 603-616.	0.9	25
32	Gastrointestinal Complications of Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 809-832.	1.2	24
33	Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 627-644.	1.0	24
34	Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis. <i>American Journal of Gastroenterology</i> , 2016, 111, 746-748.	0.2	22
35	Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2019, 64, 382-390.	1.1	22
36	Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1316-1320.	0.9	18

#	ARTICLE	IF	CITATIONS
37	Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. <i>Gastroenterology</i> , 2021, 161, 107-115.e3.	0.6	17
38	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 885-894.	0.2	15
39	Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation. <i>American Journal of Gastroenterology</i> , 2017, 112, 1621.	0.2	14
40	Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 567-574.	0.6	14
41	Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1215-1223.	0.9	13
42	<i>Pseudomonas</i> Meningitis During Vedolizumab Therapy for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2015, 110, 1631-1632.	0.2	12
43	National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1068-1078.	0.9	12
44	Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2564-2569.	1.1	10
45	Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00484.	1.3	8
46	Validation of Gene Expression Biomarker Analysis for Biopsy-based Clinical Trials in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 323-330.	0.9	7
47	Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097121.	1.4	7
48	Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1277-1284.	0.9	7
49	Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2366-2376.	0.9	6
50	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e750-e760.	2.4	6
51	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1574-1582.	1.9	5
52	Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 173-181.e5.	2.4	4
53	Su1910 EFFECT OF HISTOLOGICAL ACTIVITY ON CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS TREATED-TO-TARGET: COMPARISON OF CLINICAL VS ENDOSCOPIC VS HISTOLOGIC REMISSION. <i>Gastroenterology</i> , 2020, 158, S-698.	0.6	3
54	A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 555-562.	0.9	3

#	ARTICLE	IF	CITATIONS
55	Endoscopic Surveillance in Long-standing Colitis. Current Treatment Options in Gastroenterology, 2017, 15, 429-439.	0.3	1
56	Caseâ€“control study of the association of chronic acid suppression and social determinants of health with COVID-19 infection. Scientific Reports, 2021, 11, 20987.	1.6	1
57	Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 568-569.	1.9	0
58	Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitisâ€“authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 957-958.	1.9	0